WO2008063300A3 - Boronic acids and esters as inhibitors of fatty acid amide hydrolase - Google Patents

Boronic acids and esters as inhibitors of fatty acid amide hydrolase Download PDF

Info

Publication number
WO2008063300A3
WO2008063300A3 PCT/US2007/021626 US2007021626W WO2008063300A3 WO 2008063300 A3 WO2008063300 A3 WO 2008063300A3 US 2007021626 W US2007021626 W US 2007021626W WO 2008063300 A3 WO2008063300 A3 WO 2008063300A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
esters
fatty acid
acid amide
boronic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/021626
Other languages
French (fr)
Other versions
WO2008063300A8 (en
WO2008063300A2 (en
Inventor
Julian Adams
Mark L Behnke
Alfredo C Castro
Catherine A Evans
Louis Grenier
Michael J Grogan
Tao Liu
Daniel A Snyder
Thomas T Tibbitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinity Discovery Inc
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39323893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008063300(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK07870774.2T priority Critical patent/DK2073816T3/en
Priority to BRPI0719218-5A2A priority patent/BRPI0719218A2/en
Priority to UAA200904557A priority patent/UA101601C2/en
Priority to KR20157004938A priority patent/KR20150038363A/en
Priority to EP07870774A priority patent/EP2073816B1/en
Priority to AT07870774T priority patent/ATE524188T1/en
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Priority to ES07870774T priority patent/ES2373697T3/en
Priority to HK09112408.2A priority patent/HK1137137B/en
Priority to CA2666224A priority patent/CA2666224C/en
Priority to AU2007322268A priority patent/AU2007322268B2/en
Priority to JP2009532388A priority patent/JP5641600B2/en
Priority to MX2009003727A priority patent/MX2009003727A/en
Priority to NZ576851A priority patent/NZ576851A/en
Priority to RU2009113830/04A priority patent/RU2492174C2/en
Publication of WO2008063300A2 publication Critical patent/WO2008063300A2/en
Publication of WO2008063300A3 publication Critical patent/WO2008063300A3/en
Priority to IL197932A priority patent/IL197932A/en
Anticipated expiration legal-status Critical
Priority to NO20091620A priority patent/NO342439B1/en
Publication of WO2008063300A8 publication Critical patent/WO2008063300A8/en
Priority to IL219039A priority patent/IL219039A/en
Priority to PH12012500765A priority patent/PH12012500765A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
PCT/US2007/021626 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Ceased WO2008063300A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
MX2009003727A MX2009003727A (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty amide hydrolase.
AU2007322268A AU2007322268B2 (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
UAA200904557A UA101601C2 (en) 2006-10-10 2007-10-10 Inhibitors of fatty acid amide hydrolase
KR20157004938A KR20150038363A (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
EP07870774A EP2073816B1 (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
AT07870774T ATE524188T1 (en) 2006-10-10 2007-10-10 BORIC ACID AND ESTERS AS FATTY ACID AMIDE HYDROLASE INHIBITORS
BRPI0719218-5A2A BRPI0719218A2 (en) 2006-10-10 2007-10-10 FATTY ACID HYDROLASE AMIDE INHIBITORS
ES07870774T ES2373697T3 (en) 2006-10-10 2007-10-10 �? BORONIC CIDES AND ESTERS AS INHIBITORS OF AMIDAS HYDROLASSES OF �? FAT CIDES.
HK09112408.2A HK1137137B (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
CA2666224A CA2666224C (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
JP2009532388A JP5641600B2 (en) 2006-10-10 2007-10-10 Inhibitors of fatty acid amide hydrolase
DK07870774.2T DK2073816T3 (en) 2006-10-10 2007-10-10 Boric acids and esters as inhibitors of fatty acid amide hydrolase
RU2009113830/04A RU2492174C2 (en) 2006-10-10 2007-10-10 Inhibitors of fatty acid amide hydrolase
NZ576851A NZ576851A (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase
IL197932A IL197932A (en) 2006-10-10 2009-04-05 Boronic acids and esters as inhibitors of fatty acid amide hydrolase and pharmaceutical compositions and medicaments comprising them
NO20091620A NO342439B1 (en) 2006-10-10 2009-04-23 Chemical compounds, pharmaceutical composition and drug comprising the same and drug comprising the same for the treatment of disease »
IL219039A IL219039A (en) 2006-10-10 2012-04-04 תכשירים רפואיים המכילים fatty acid amide hydrolase (faah) ושימושיהם בטיפול במחלות המתווכות על–ידי faah
PH12012500765A PH12012500765A1 (en) 2006-10-10 2012-04-18 Boronic acids and esters as inhibitors of fatty acid amide hydrolase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85052006P 2006-10-10 2006-10-10
US60/850,520 2006-10-10

Publications (3)

Publication Number Publication Date
WO2008063300A2 WO2008063300A2 (en) 2008-05-29
WO2008063300A3 true WO2008063300A3 (en) 2008-07-17
WO2008063300A8 WO2008063300A8 (en) 2009-06-11

Family

ID=39323893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021626 Ceased WO2008063300A2 (en) 2006-10-10 2007-10-10 Boronic acids and esters as inhibitors of fatty acid amide hydrolase

Country Status (26)

Country Link
US (6) US7947663B2 (en)
EP (4) EP2399584A1 (en)
JP (2) JP5641600B2 (en)
KR (2) KR20090085623A (en)
CN (2) CN101563089A (en)
AR (1) AR063165A1 (en)
AT (1) ATE524188T1 (en)
AU (1) AU2007322268B2 (en)
BR (1) BRPI0719218A2 (en)
CA (1) CA2666224C (en)
CL (1) CL2007002910A1 (en)
DK (1) DK2073816T3 (en)
ES (1) ES2373697T3 (en)
IL (2) IL197932A (en)
JO (1) JO3598B1 (en)
MX (1) MX2009003727A (en)
NO (1) NO342439B1 (en)
NZ (1) NZ576851A (en)
PE (1) PE20081172A1 (en)
PH (1) PH12012500765A1 (en)
PT (1) PT2073816E (en)
RU (1) RU2492174C2 (en)
SG (3) SG175608A1 (en)
TW (1) TWI451870B (en)
UA (1) UA101601C2 (en)
WO (1) WO2008063300A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3598B1 (en) 2006-10-10 2020-07-05 Infinity Discovery Inc Boronic acids and esters as inhibitors of fatty acid amide hydrolase
SI2076508T1 (en) 2006-10-18 2011-04-29 Pfizer Prod Inc Biaryl ether urea compounds
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
TWI469979B (en) * 2008-12-24 2015-01-21 Bial Portela & Ca Sa Faah inhibitor, and pharmaceutical composition and use thereof
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010118159A1 (en) * 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
AR076687A1 (en) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc ISOXAZOLINS AS INHIBITORS OF THE AMIDAHIDROLASA OF FATTY ACIDS AND PHARMACEUTICAL COM-POSITIONS CONTAINING THEM
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
EP2531511A1 (en) * 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
WO2011151822A1 (en) * 2010-05-31 2011-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. 3-substituted vinylboronates and uses thereof
WO2012112670A1 (en) * 2011-02-16 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Novel lipogenic inhibitors and uses thereof
WO2013049332A1 (en) * 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
AU2013280980B2 (en) * 2012-06-25 2017-10-19 Thomas Jefferson University Compositions and methods for treating cancer with aberrant lipogenic signaling
BR112015000308A2 (en) * 2012-07-10 2017-06-27 Bayer Pharma AG method for preparing substituted triazolopyridines
EP2909216B1 (en) * 2012-10-17 2016-12-21 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Compositions and methods for improving glucose uptake
CA2914521A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
FR3051792B1 (en) * 2016-05-30 2020-01-24 Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris NOVEL COMPOUNDS, FUNCTIONALIZED DIOXOBOROLANE OR DIOXABORINANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USES THEREOF
WO2018164959A1 (en) * 2017-03-09 2018-09-13 The Penn State Research Foundation Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
CN108409727A (en) * 2017-10-25 2018-08-17 巨德峰 A kind of inhibitors of fatty amide hydrolase and preparation method thereof
US12023332B2 (en) 2018-03-05 2024-07-02 Wylder Nation Foundation Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
EP3632908A1 (en) * 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
CU20210023A7 (en) * 2018-10-05 2021-10-12 Pfizer PYRIDINYL 1,2-OXABOROLAN-2-OL PHOSPHODIESTERASE 4 SUBSTITUTE PHENYL INHIBITORS
US20220289775A1 (en) * 2019-02-01 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University ENPP1 Inhibitors and Methods of Modulating Immune Response
ES2960987T3 (en) * 2019-04-12 2024-03-07 Riboscience Llc Bicyclic heteroaryl derivatives as inhibitors of ectonucleotide pyrophosphatase phosphodiesterase 1
EP4041246B1 (en) * 2019-10-07 2024-12-04 Cornell University Antimicrobial and antiviral effects of c2-c7alkyl boronic acids
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
US11395829B2 (en) * 2019-11-21 2022-07-26 Myongji University Industry And Academia Cooperation Foundation Inhibitors of metallo-beta-lactamases produced by multidrug-resistant bacteria
CN112321625A (en) * 2020-11-30 2021-02-05 河西学院 A kind of MIDA boronate-naphthalimide compound based on folic acid and its preparation and application
CN117279924A (en) * 2021-05-04 2023-12-22 西格马-奥尔德里奇有限责任公司 Chemically linkable nuclear targeting tags
WO2024155644A2 (en) * 2023-01-18 2024-07-25 Uwm Research Foundation, Inc. Combination therapy for cancer using ros-activated prodrugs and ros-amplifying therapeutics

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035300A1 (en) * 1994-06-22 1995-12-28 Macronex, Inc. N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
WO2000042213A1 (en) * 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
WO2002057273A1 (en) * 2001-01-20 2002-07-25 Trigen Limited Serine protease inhibitors comprising a hydrogen-bond acceptor
WO2002059155A2 (en) * 2001-01-04 2002-08-01 University Of Leeds Modulation of calcium channel activity
EP1236726A1 (en) * 1999-12-03 2002-09-04 Ono Pharmaceutical Co., Ltd. Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient
WO2002085916A1 (en) * 2001-04-24 2002-10-31 University Of North Carolina At Chapel Hill 9-[(5-dihydroxyboryl)-pentyl] purines, inhibitor of inflammatory cytokines
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
EP1444981A1 (en) * 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
WO2004081008A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
US20050250825A1 (en) * 2000-08-23 2005-11-10 Brooks Dawn A Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
WO2006050054A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050053A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050236A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006053250A2 (en) * 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
US20060135423A1 (en) * 2004-12-21 2006-06-22 Jayakrishna Ambati VEGF-A as an inhibitor of angiogenesis and methods of using same
WO2006099261A2 (en) * 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
WO2007028104A2 (en) * 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
WO2007078340A2 (en) * 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007095638A2 (en) * 2006-02-16 2007-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
WO2007146965A2 (en) * 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Compounds for the treatment of periodontal disease
WO2008002674A2 (en) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
WO2008020920A1 (en) * 2006-08-15 2008-02-21 Duke University Ros-sensitive iron chelators and methods of using the same

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025A (en) * 1847-03-20 Horatio allen
US6013A (en) * 1849-01-09 Improvement in molding and compressing cores
DE445224C (en) 1924-04-09 1927-06-01 Edward D Feldman Frame with beveled side edges
US2693688A (en) * 1951-11-23 1954-11-09 Bocchino Ernest Wrist cigarette lighter
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1268808A (en) 1985-07-23 1990-05-08 Alan G. Macdiarmid High capacity polyaniline electrodes
CH671400A5 (en) 1986-12-17 1989-08-31 Nii Prikladnych
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3807862A1 (en) 1988-03-10 1989-09-21 Merck Patent Gmbh SMEQUATIC LIQUID CRYSTAL PHASE
US5273680A (en) 1988-03-10 1993-12-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluorinated oligophenyls and their use in liquid crystal materials
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
EP0440082B1 (en) 1990-02-01 1998-04-15 MERCK PATENT GmbH Method for the conversion of fluorinated aromatic compounds using electrophiles
DE4014488A1 (en) 1990-05-07 1991-11-14 Merck Patent Gmbh Novel dioxa:borinane(s) - for use in liq. crystal media for optical displays
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
EP0501268B1 (en) 1991-02-25 1996-06-12 F. Hoffmann-La Roche Ag Liquid crystal compounds ending with a 1-alkinyl group
CZ230593A3 (en) 1991-04-30 1994-04-13 Procter & Gamble Liquid detergents with arylboric acid
GB2258232B (en) 1991-07-31 1995-03-15 Merck Patent Gmbh Alkoxymethylene fluoroterphenyls and liquid crystalline medium
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
CH683522A5 (en) 1992-03-13 1994-03-31 Hoffmann La Roche Process for the preparation of diaryls.
FR2688783A1 (en) 1992-03-23 1993-09-24 Rhone Poulenc Chimie NOVEL BORONES OF ONIUM OR ORGANOMETALLIC COMPLEX CATIONIC PRIMERS FOR POLYMERIZATION.
FR2688790B1 (en) 1992-03-23 1994-05-13 Rhone Poulenc Chimie COMPOSITIONS BASED ON POLYORGANOSILOXANES WITH CROSSLINKABLE FUNCTIONAL GROUPS AND THEIR USE FOR THE PRODUCTION OF ANTI-ADHESIVE COATINGS.
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
PL167141B1 (en) 1992-05-12 1995-07-31 Wojskowa Akad Tech The method of obtaining liquid crystal compounds containing 1,3-dioxa -2-borane ring
JP3255965B2 (en) 1992-05-26 2002-02-12 昭和シェル石油株式会社 Antiferroelectric liquid crystal compound
DE4220065A1 (en) 1992-06-19 1993-12-23 Merck Patent Gmbh Linear poly:cyclic pyrimidine and 2-phenyl-5-bromo-pyrimidine cpds. - aare useful in liquid crystal medium and as intermediates
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9220189D0 (en) 1992-09-24 1992-11-04 Central Research Lab Ltd Dioxane derivatives
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
GB9220750D0 (en) 1992-10-02 1992-11-18 Merck Patent Gmbh Liquid crystalline material forming ananisotropic
DE4236103A1 (en) 1992-10-26 1994-04-28 Hoechst Ag Process for the cross-coupling of aromatic boronic acids with aromatic halogen compounds or perfluoroalkyl sulfonates
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
EP0604289B1 (en) 1992-12-17 1997-09-24 Valeo Systemes D'essuyage Method and device for supplying power to an electric motor for driving a windscreen wiper of a automotive vehicle
TW240217B (en) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
FR2702485B1 (en) 1993-03-10 1995-04-14 Rhone Poulenc Chimie Compositions based on cationically crosslinkable polyorganosiloxanes and their use in the field of paper anti-adhesion, protection of optical fibers and printed circuits.
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
GB2278841A (en) * 1993-06-11 1994-12-14 Secr Defence Liquid crystal compounds, mixtures and devices
US5417885A (en) 1993-08-03 1995-05-23 Showa Shell Sekiyu Kabushiki Kaisha Antiferroelectric liquid crystal compound
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
JPH07145174A (en) 1993-11-22 1995-06-06 Takeda Chem Ind Ltd Dioxaborinane compound, its production, liquid crystal composition containing the compound and liquid crystal light-modulator produced by using the composition
JPH07165717A (en) 1993-12-16 1995-06-27 Sumitomo Chem Co Ltd Heterocyclic compound and method for producing the same
JPH07206715A (en) 1994-01-21 1995-08-08 Sumitomo Chem Co Ltd Process for producing heterocyclic compound
DE19502178A1 (en) 1994-01-27 1995-08-03 Hoechst Ag Novel 1,3,4-thiadiazole(s) useful as liq. crystal intermediates
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
GB2290787B (en) 1994-06-30 1998-10-28 Merck Patent Gmbh Benzene derivatives and a liquid-crystalline medium
JP3702426B2 (en) 1994-08-03 2005-10-05 関東化学株式会社 Trifluoromethylbenzene derivative and liquid crystal composition
FR2724660B1 (en) 1994-09-16 1997-01-31 Rhone Poulenc Chimie CATIONIC CROSSLINKING INITIATORS OF POLYMERS WITH ORGANOFUNCTIONAL GROUPS, COMPOSITIONS BASED ON CROSSLINKABLE POLYORGANOSILOXANE AND CONTAINING THESE INITIATORS AND APPLICATION OF THE SAID COMPOSITIONS IN ANTI-ADHERENCE
JPH0892137A (en) 1994-09-26 1996-04-09 Sumitomo Chem Co Ltd Aromatic ester compound, production method and use thereof
FR2727416A1 (en) 1994-11-24 1996-05-31 Rhone Poulenc Chimie Heat activated cationic polymerisation and crosslinking initiators
DE4445224B4 (en) 1994-12-17 2014-03-27 Merck Patent Gmbh benzene derivatives
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
DE69629413T2 (en) * 1995-04-24 2004-04-01 Semiconductor Energy Laboratory Co., Ltd., Atsugi Liquid crystal compound and liquid crystal composition containing it
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
JP3783246B2 (en) 1995-07-18 2006-06-07 大日本インキ化学工業株式会社 p-terphenyl derivatives
DE59605843D1 (en) 1995-07-28 2000-10-12 Rolic Ag Zug Photocrosslinkable liquid crystalline 1,2-phenylene derivatives
JP3476832B2 (en) 1995-08-09 2003-12-10 チッソ株式会社 Cyclohexane derivative and liquid crystal composition
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
FR2745288B1 (en) 1996-02-27 1998-04-17 Adir NOVEL BORONIC ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9605334D0 (en) 1996-03-13 1996-05-15 British Nuclear Fuels Plc Biodecontamination reactor
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP3555325B2 (en) 1996-04-12 2004-08-18 チッソ株式会社 Method for producing biaryl derivative
ATE221037T1 (en) 1996-06-03 2002-08-15 Basf Ag 1,4-DIARYL-2-FLUORO-2-BUTENE AS INSECTICIDES AND ACARICIDES
US5849958A (en) 1997-03-17 1998-12-15 American Cyanamid Company 1,4,diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
ZA974582B (en) 1996-06-03 1998-11-26 American Cyanamid Co Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds
US5998673A (en) 1996-06-03 1999-12-07 American Cyanamid Company 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
US5892131A (en) 1997-05-29 1999-04-06 American Cyanamid Company Process for the preparation of pesticidal fluoroolefin compounds
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
JPH101450A (en) * 1996-06-14 1998-01-06 Chisso Corp Fluorine-substituted alkyl ether compound, liquid crystal compound and liquid crystal display element
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH1025261A (en) 1996-07-09 1998-01-27 Chisso Corp Production of phenol derivative
PT933346E (en) 1996-07-31 2004-03-31 Shionogi & Co NEW P-TERPHENYL COMPOUNDS
JP3899557B2 (en) 1996-08-21 2007-03-28 大日本インキ化学工業株式会社 Fluorobibiphenyl derivatives
FR2752582B1 (en) 1996-08-21 2003-06-13 Rhone Poulenc Chimie POLYORGANOSILOXANE COMPOSITIONS HAVING CROSS-LINKED FUNCTIONAL GROUPS AND THEIR USE FOR MAKING ANTI-ADHERENT COATINGS
JP4526605B2 (en) 1996-08-28 2010-08-18 チッソ株式会社 Tetracyclic compound having lateral halogen substituent and liquid crystal composition
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
JPH10152491A (en) 1996-11-21 1998-06-09 Dai Ichi Seiyaku Co Ltd Crystalline carbapenem compound
EP0959061A4 (en) 1996-11-25 2000-08-23 Chisso Corp 3,3'-DIFLUOROBIPHENYL DERIVATIVES, LIQUID CRYSTAL COMPOSITIONS, AND LIQUID CRYSTAL DISPLAY ELEMENTS
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
FR2757530A1 (en) 1996-12-24 1998-06-26 Rhodia Chimie Sa USE FOR STEREOPHOTOLITHOGRAPHY - A CATIONIC PHOTORETICULABLE LIQUID COMPOSITION COMPRISING A PHOTOAMORER OF THE ONIUM SALTS OR ORGANOMETALLIC COMPLEX TYPE
FR2757870B1 (en) 1996-12-30 1999-03-26 Rhodia Chimie Sa USE OF CATIONICALLY CROSSLINKABLE SILICONE COMPOSITIONS AND AN ONIUM BORATE PHOTO-PRIMER FOR COATING FLAT JOINTS, PARTICULARLY CYLINDER JOINTS
FR2758329B1 (en) 1997-01-16 1999-02-12 Synthelabo BORONIC IMIDAZOLE-4-BUTANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2758560B1 (en) 1997-01-20 2000-02-04 Adir NEW DERIVATIVES OF AMINOPHENYLBORONIC ACIDS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2758723B1 (en) 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
JP4098368B2 (en) 1997-02-13 2008-06-11 チッソ株式会社 Liquid crystalline compound, liquid crystal composition and liquid crystal display element having bicyclo [1.1.1] pentane structure
DE19710614A1 (en) 1997-03-14 1998-09-17 Hoechst Ag Di:substituted 1,2,4-thiadiazole derivative preparation
EE9900435A (en) * 1997-04-01 2000-04-17 Astra Pharmaceuticals Limited Novel pyridine derivatives and pharmaceutical compositions containing them
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6075014A (en) 1997-06-13 2000-06-13 Northwestern University Inhibitors of β-lactamases and uses therefor
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
PL343316A1 (en) * 1998-03-31 2001-08-13 Shionogi & Co Process for producing 5-hydroxybenzo[b]thiophene-3-carboxylic acid derivatives
DZ2769A1 (en) 1998-04-17 2003-12-01 Lilly Co Eli Substituted tricyclics.
DE19909761A1 (en) 1998-04-17 1999-10-21 Merck Patent Gmbh New optically inactive benzo(b)furan, benzo(1,2-b:4,5-b')difuran and benzo(1,2-b:5,4-b')difuran derivatives, used in liquid crystal media
CA2269561C (en) * 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
JP2000001463A (en) 1998-06-12 2000-01-07 Dainippon Ink & Chem Inc Method for producing 4-cyanobenzene derivative
GB9814450D0 (en) 1998-07-04 1998-09-02 Sharp Kk Novel compounds
GB2339778A (en) 1998-07-17 2000-02-09 Secr Defence Terphenyl Liquid Crystals
WO2000020466A1 (en) 1998-10-01 2000-04-13 Targor Gmbh Catalyst system
DE19857765A1 (en) 1998-12-15 2000-06-21 Clariant Gmbh Process for the preparation of para-oxadiazolyl-phenyl-boronic acids
DE19858594A1 (en) 1998-12-18 2000-06-21 Merck Patent Gmbh Cyanobenzene-boronic acid or ester preparation in high yield comprises treating halo-benzonitrile and trialkyl borate with alkyl lithium, used as intermediate e.g. for liquid crystals, pesticides or drugs
CN1330656A (en) 1998-12-19 2002-01-09 巴塞尔聚烯烃股份有限公司 The preparation method of monoorganoborane or diorganoborane
JP4507294B2 (en) 1999-05-27 2010-07-21 チッソ株式会社 Method for producing biaryl derivative
JP2001039975A (en) 1999-07-26 2001-02-13 Eisai Co Ltd Crystal of sulfoxide derivative and its production
EP1214306A1 (en) 1999-09-21 2002-06-19 Qinetiq Limited Liquid crystal compounds
US6309406B1 (en) 1999-11-24 2001-10-30 Hamit-Darwin-Fresh, Inc. Apparatus and method for inducing epileptic seizures in test animals for anticonvulsant drug screening
US20030096854A1 (en) 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
FR2805273B1 (en) 2000-02-18 2006-08-11 Rhodia Chimie Sa SURFACE TREATMENT OF PLASTIC MATERIAL WITH A POLYMERIZABLE AND / OR CROSS-REACTIVE REACTIVE FUNCTION COMPOSITION
DE10009714A1 (en) 2000-03-01 2001-09-06 Targor Gmbh Preparation of main group III element mono- or di-organo-compound, e.g. halogenated diorgano-hydroxyborane used as precursor for cocatalyst in olefin polymerization with metallocene, uses two-stage, preferably one-pot reaction
EP1130114A1 (en) * 2000-03-03 2001-09-05 Dr. van Haeringen Laboratorium B.V. Universal variable fragments
GB2362882A (en) 2000-06-02 2001-12-05 Sharp Kk Liquid crystalline optionally laterally fluorinated terphenyl with chiral 3,4-di[(un)saturated-alkoxy]butoxy or 1,4-di[(un)saturated-alkoxy]but-2-oxy terminus
CA2419238A1 (en) 2000-08-16 2002-02-21 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
US6927216B2 (en) 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
ATE449173T1 (en) 2000-10-05 2009-12-15 Millennium Pharm Inc 32144, A HUMAN FATTY ACID AMIDE HYDROLASE AND USES THEREOF
JP4721027B2 (en) 2001-03-29 2011-07-13 Ｄｉｃ株式会社 Method for producing phenylpyrimidine derivative
US6890940B2 (en) * 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US7962950B2 (en) * 2001-06-29 2011-06-14 Hewlett-Packard Development Company, L.P. System and method for file system mandatory access control
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US6617125B2 (en) 2001-06-29 2003-09-09 Perkinelmer Life Sciences, Inc. Compositions for enhanced catalyzed reporter deposition
ATE303389T1 (en) 2001-07-09 2005-09-15 Merck Patent Gmbh THIENOTHIOPHENE DERIVATIVES
EP1436332A2 (en) 2001-10-12 2004-07-14 Dow Global Technologies Inc. Metal complex compositions and their use as catalysts to produce polydienes
ATE360054T1 (en) 2001-11-07 2007-05-15 Merck Patent Gmbh LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DISPLAY
GB0126844D0 (en) 2001-11-08 2002-01-02 Qinetiq Ltd Novel compounds
DE10201764A1 (en) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituted 4-aminopyridine derivatives
WO2003064484A1 (en) 2002-01-28 2003-08-07 Dow Global Technologies Inc. Metal complex compositions based on cobalt and their use as polymerization catalyst for olefins and dienes
DE10206759A1 (en) * 2002-02-19 2003-08-28 Dragoco Gerberding Co Ag Use of 1,2-alkanediol mixture as an antimicrobial agent, e.g. for treating body odor, acne or mycoses or preserving perishable products
DE10211597A1 (en) 2002-03-15 2003-10-02 Merck Patent Gmbh Process for the production of ring connections
MXPA04012783A (en) 2002-06-27 2005-02-24 Fujisawa Pharmaceutical Co Aminoalcohol derivatives.
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids
EP1388538B1 (en) * 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
US20040020447A1 (en) * 2002-08-05 2004-02-05 William Taylor Method and apparatus for advancing air into a fuel reformer by use of an engine vacuum
US20040115475A1 (en) 2002-08-14 2004-06-17 Matsushita Electric Industrial Co., Ltd. Aromatic methylidene compound, methylstyrul compound for producing the same, production electroluminescent element
CA2505361A1 (en) * 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
WO2004048357A1 (en) 2002-11-27 2004-06-10 Merck Patent Gmbh Tetrahydropyran derivatives
US6924269B2 (en) 2002-12-04 2005-08-02 Vdf Futureceuticals, Inc. Enzyme inhibitors and methods therefor
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
ATE409176T1 (en) 2003-02-21 2008-10-15 Chiesi Farma Spa 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
WO2004080989A1 (en) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited Process for production of furan compounds
DE10325438A1 (en) 2003-05-21 2004-12-09 Bayer Cropscience Ag Difluormethylbenzanilide
AU2004267007C1 (en) 2003-06-03 2010-04-29 Melinta Subsidiary Corp. Biaryl heterocyclic compounds and methods of making and using the same
WO2005004799A2 (en) * 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF
US7017590B2 (en) * 2003-06-10 2006-03-28 Vivienne Joyce Mackinder Microwavable hair curling device
BRPI0411582A (en) 2003-06-16 2006-08-08 Anacor Pharmaceuticals Inc hydrolytically resistant boron-containing therapeutic substances and method of use
WO2004113167A1 (en) * 2003-06-25 2004-12-29 Valery Ilyich Smetannikov Device for cargo disposition in an aircraft and for jettison said cargo therefrom
DE10337497A1 (en) 2003-08-14 2005-03-10 Bayer Cropscience Ag 4-biphenyl-pyrazolidine-3,5-dione derivatives
WO2005037227A2 (en) 2003-10-16 2005-04-28 Microbia, Inc. Selective cox-2 inhibitors
EP1682076A4 (en) * 2003-10-31 2008-02-06 Fulcrum Pharmaceuticals Inc Inhibitors of CORONAVIRUS PROTEASE AND METHOD OF APPLICATION THEREOF
DE602004008100T2 (en) 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-BIARYLYL-1-phenylazetidin-2-ONE
US20070010559A1 (en) 2003-11-25 2007-01-11 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
JP2007512263A (en) * 2003-11-25 2007-05-17 ノボ　ノルディスク　アクティーゼルスカブ Indole derivatives for use as chemical uncouplers
JP4491666B2 (en) 2003-12-02 2010-06-30 東ソー株式会社 Method for producing arylamine derivative having fluorene skeleton and synthetic intermediate thereof
GB2410745B (en) 2004-02-06 2007-07-25 Merck Patent Gmbh Cholestanyl derivatives
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR200349335Y1 (en) 2004-02-21 2004-05-06 김노석 Valve for water saving
DE502005000317D1 (en) * 2004-03-19 2007-03-08 Alfmeier Praez Ag Vehicle seat with a swivel-mounted headrest
EP2264033A1 (en) * 2004-07-27 2010-12-22 SGX Pharmaceuticals, Inc. 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
TWM265652U (en) * 2004-08-03 2005-05-21 Premier Image Technology Corp Solid integration rod for DLP
DE102004041530A1 (en) 2004-08-27 2006-03-02 Bayer Cropscience Ag biphenyl thiazole carboxamides
DE102004041532A1 (en) 2004-08-27 2006-03-02 Bayer Cropscience Ag biphenyl thiazole carboxamides
DE102005023834A1 (en) 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituted [(phenylethanoyl) amino] benzamide
WO2006060625A2 (en) 2004-12-02 2006-06-08 Displaytech, Inc. Liquid crystal compositions comprising an organogermanium compound and methods for using the same
US20060211698A1 (en) 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
JP5038912B2 (en) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ，インコーポレイテッド Boron-containing small molecule
DE112006000379T5 (en) 2005-02-22 2008-02-07 Sumation Co. Ltd. Arylene polymers with a large band gap
GB2424881B (en) 2005-04-07 2010-11-24 Merck Patent Gmbh Halophenyl derivatives of bisalkylfluorene
JP4792796B2 (en) 2005-04-08 2011-10-12 東ソー株式会社 2,3-Dihalobiphenylene derivative, precursor compound thereof and production method thereof
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
JP2008540573A (en) 2005-05-13 2008-11-20 マイクロビア インコーポレーテッド 4-Bialyl-1-phenylazetidin-2-ones
US7674876B2 (en) 2005-05-25 2010-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthesis of novel monomers containing the trifluorovinylidene group and the cyanato group and polymers thereof
US20090291988A1 (en) 2005-06-14 2009-11-26 Renata Oballa Reversible Inhibitors of Monoamine Oxidase A and B
KR100659088B1 (en) 2005-07-15 2006-12-21 삼성에스디아이 주식회사 Difluoropyridine compound and organic light emitting device using the same
KR100730140B1 (en) 2005-07-15 2007-06-19 삼성에스디아이 주식회사 Triazine Compound and Organic Light-Emitting Device Using the Same
DE102005037925A1 (en) 2005-08-11 2007-02-15 Merck Patent Gmbh New hydro-cyclopentanaphthalene compound, useful as a component for a liquid crystalline medium, which is used as a component for an electrooptical display element
US7999137B2 (en) 2005-09-13 2011-08-16 Bayer Cropscience Ag Pesticide bi-phenyl-amidine derivatives
DE602006011363D1 (en) 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituted steroid derivatives as L-CPT1 inhibitors
US8496835B2 (en) 2005-12-02 2013-07-30 Sachem, Inc. Anion-exchange displacement chromatography process and anionic organic compounds for use as displacer compounds in anion-exchange displacement chromatography process
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
DE102007009944B4 (en) 2006-03-15 2016-04-28 Merck Patent Gmbh Liquid-crystalline medium and its use
TWI417095B (en) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
AU2007240082A1 (en) 2006-04-13 2007-10-25 Aegera Therapeutics Inc. Use of imidazo[2,1-b)]-1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain
JP5145753B2 (en) 2006-04-20 2013-02-20 Ｊｎｃ株式会社 Compound having fluoroisopropyl group as side chain and liquid crystal composition using the same
CA2653056A1 (en) 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
JP4881095B2 (en) * 2006-07-28 2012-02-22 株式会社東海理化電機製作所 Key system
CN101506330B (en) 2006-08-16 2013-11-06 默克专利股份有限公司 New cyclohexene-compounds useful as a component in a liquid crystal medium
DE502007004625D1 (en) 2006-09-13 2010-09-16 Merck Patent Gmbh Fluorophenyl compounds for liquid crystalline mixtures
EP2059227A2 (en) * 2006-09-26 2009-05-20 Aeris Therapeutics, Inc. Polymer systems for lung volume reduction therapy
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
JO3598B1 (en) * 2006-10-10 2020-07-05 Infinity Discovery Inc Boronic acids and esters as inhibitors of fatty acid amide hydrolase
SI2076508T1 (en) 2006-10-18 2011-04-29 Pfizer Prod Inc Biaryl ether urea compounds
CN101616883B (en) 2007-01-24 2014-06-18 Jnc株式会社 Liquid crystal compound, liquid crystal composition and liquid crystal display element
WO2008105286A1 (en) 2007-02-28 2008-09-04 Chisso Corporation Pentacyclic liquid crystal compound having cf2o bonding group, liquid crystal composition and liquid crystal display
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US20080280991A1 (en) 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
DE102007030269B4 (en) * 2007-06-28 2014-07-17 Mitsubishi Hitachi Power Systems Europe Gmbh Pulverized coal burner for burning fuel supplied in dense phase conveying
WO2009011904A1 (en) 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US8237002B2 (en) 2008-05-08 2012-08-07 Sumitomo Chemical Company, Limited Method for producing unsaturated organic compound
DE102008023801A1 (en) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituted imidazo and triazolopyrimidines, imidazo and pyrazolopyrazines and imidazotriazines
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2531511A1 (en) 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035300A1 (en) * 1994-06-22 1995-12-28 Macronex, Inc. N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
WO2000042213A1 (en) * 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
EP1236726A1 (en) * 1999-12-03 2002-09-04 Ono Pharmaceutical Co., Ltd. Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient
US20050250825A1 (en) * 2000-08-23 2005-11-10 Brooks Dawn A Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
WO2002059155A2 (en) * 2001-01-04 2002-08-01 University Of Leeds Modulation of calcium channel activity
WO2002057273A1 (en) * 2001-01-20 2002-07-25 Trigen Limited Serine protease inhibitors comprising a hydrogen-bond acceptor
WO2002085916A1 (en) * 2001-04-24 2002-10-31 University Of North Carolina At Chapel Hill 9-[(5-dihydroxyboryl)-pentyl] purines, inhibitor of inflammatory cytokines
EP1444981A1 (en) * 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
WO2004081008A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
WO2006050053A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050054A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050236A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006053250A2 (en) * 2004-11-12 2006-05-18 Trustees Of Tufts College Lipase inhibitors
US20060135423A1 (en) * 2004-12-21 2006-06-22 Jayakrishna Ambati VEGF-A as an inhibitor of angiogenesis and methods of using same
WO2006099261A2 (en) * 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
WO2007028104A2 (en) * 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
WO2007078340A2 (en) * 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007095638A2 (en) * 2006-02-16 2007-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
WO2007146965A2 (en) * 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Compounds for the treatment of periodontal disease
WO2008002674A2 (en) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
WO2008020920A1 (en) * 2006-08-15 2008-02-21 Duke University Ros-sensitive iron chelators and methods of using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAUJOLLE F ET AL: "[The effect of organoboron derivatives on cardiovascular and ventilatory manifestations of electroshock]", AGRESSOLOGIE: REVUE INTERNATIONALE DE PHYSIO-BIOLOGIE ET DE PHARMACOLOGIE APPLIQUÉES AUX EFFETS DE L'AGRESSION 1967 SEP-OCT, vol. 8, no. 5, September 1967 (1967-09-01), pages 425 - 432, XP009099800, ISSN: 0002-1148 *
CAUJOLLE F ET AL: "ETUDE COMPAREE DU POUVOIR RENFORCATEUR DES ORGANOBORIQUES A L'EGARD DES HYPNOTIQUES//POTENTIATION OF HYPNOTICS BY ORGANOBORON DERIVATIVES", AGRESSOLOGIE, XX, XX, vol. 10, no. 1, 1 January 1969 (1969-01-01), pages 51 - 54, XP009021780 *
MILLER III M C ET AL: "The hypolipidemic and anti-inflammatory activity of boronated aromatic amino acids in CF1 male mice", METAL-BASED DRUGS 1999 IL, vol. 6, no. 6, 1999, pages 337 - 344, XP007904657, ISSN: 0793-0291 *
TANAKA S ET AL: "SUPPRESSION OF ARTHRITIS BY THE INHIBITORS OF DIPEPTIDYL PEPTIDASE IV", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 19, no. 1, 1 January 1997 (1997-01-01), pages 15 - 24, XP000921050, ISSN: 0192-0561 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors

Also Published As

Publication number Publication date
CN104230971A (en) 2014-12-24
US8349814B2 (en) 2013-01-08
IL197932A (en) 2013-11-28
US20140121183A1 (en) 2014-05-01
US20090099131A1 (en) 2009-04-16
ATE524188T1 (en) 2011-09-15
US7947663B2 (en) 2011-05-24
KR20090085623A (en) 2009-08-07
DK2073816T3 (en) 2011-12-12
CA2666224C (en) 2017-07-11
US9108989B2 (en) 2015-08-18
AR063165A1 (en) 2008-12-30
CN104230971B (en) 2017-11-24
JP2010505955A (en) 2010-02-25
CL2007002910A1 (en) 2008-07-04
BRPI0719218A2 (en) 2014-03-18
ES2373697T3 (en) 2012-02-07
KR20150038363A (en) 2015-04-08
US8329675B2 (en) 2012-12-11
RU2492174C2 (en) 2013-09-10
EP2399585A1 (en) 2011-12-28
PH12012500765A1 (en) 2014-09-08
RU2009113830A (en) 2010-11-20
UA101601C2 (en) 2013-04-25
NZ576851A (en) 2012-09-28
TWI451870B (en) 2014-09-11
IL197932A0 (en) 2009-12-24
AU2007322268A1 (en) 2008-05-29
TW200820979A (en) 2008-05-16
US20110224171A1 (en) 2011-09-15
WO2008063300A8 (en) 2009-06-11
AU2007322268B2 (en) 2013-05-30
MX2009003727A (en) 2009-06-26
CN101563089A (en) 2009-10-21
SG10201908757TA (en) 2019-10-30
PT2073816E (en) 2011-12-15
IL219039A0 (en) 2012-05-31
US20110230440A1 (en) 2011-09-22
JO3598B1 (en) 2020-07-05
JP2014114305A (en) 2014-06-26
PE20081172A1 (en) 2008-09-30
CA2666224A1 (en) 2008-05-29
SG175608A1 (en) 2011-11-28
NO342439B1 (en) 2018-05-22
US8629125B2 (en) 2014-01-14
NO20091620L (en) 2009-07-09
EP2399584A1 (en) 2011-12-28
JP5641600B2 (en) 2014-12-17
EP2404607A1 (en) 2012-01-11
HK1137137A1 (en) 2010-07-23
SG10201502266RA (en) 2015-05-28
EP2073816A2 (en) 2009-07-01
EP2073816B1 (en) 2011-09-14
IL219039A (en) 2015-07-30
WO2008063300A2 (en) 2008-05-29
JP5710805B2 (en) 2015-04-30
US20130059819A1 (en) 2013-03-07
US20150344503A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
WO2008063300A8 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
EP2352497A4 (en) COMPOSITIONS CONTAINING DELTA-9-THC AMINO ACID ESTERS AND PROCESS FOR PREPARING THE SAME
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
IL198979A (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2010074588A8 (en) Pharmaceutical compounds
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2008024139A3 (en) Inhibitors of fatty acid amide hydrolase
WO2007140005A3 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
UA96156C2 (en) Docosahexaenoic acid esters and use thereof for the treatment and prevention of cardiovascular disease
MX2012006490A (en) Azocyclic inhibitors of fatty acid amide hydrolase.
WO2009026446A8 (en) Hdac inhibitors
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
WO2011047055A8 (en) Novel mek inhibitors, useful in the treatment of diseases
EA200901237A1 (en) APPLICATION OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN
EP2417115A4 (en) Inhibitors of fatty acid amide hydrolase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780038044.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870774

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007870774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007322268

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 197932

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/003727

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2666224

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009532388

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12009500680

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1404/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007322268

Country of ref document: AU

Date of ref document: 20071010

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 576851

Country of ref document: NZ

Ref document number: 1020097009547

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009113830

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 219039

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12012500765

Country of ref document: PH

ENP Entry into the national phase

Ref document number: PI0719218

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090413

WWE Wipo information: entry into national phase

Ref document number: 1020157004938

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020167008130

Country of ref document: KR